Blueprint Medicines Corporation

Entasis Therapeutics, Inc.

Other

Astrazeneca Ab

Glaxosmithkline LLC

Neil Bifulco

Chandrasekhar V Miduturu

Joseph L Kim

Brian Lewis Hodous

Mui Cheung

Natasja Brooijmans

Steven Mark Wenglowsky

Lucian V DiPietro

Douglas Wilson

Janelle Comita-Prevoir

Emanuele Perola

Alex Gregory Waterson

Bolin Geng

Hoan Huynh

Thomas Francois Durand-Reville

Liang Zhao

Brian A Sherer

Joseph Wendell Wilson

David Edward Uehling

Brendan Chen

Robert Dale Hubbard

Jennifer Gabriel Badiang

Hui Xiong

Satenig Guler

Shanta Bist

Philip D Ramsden

Richard Vargas

Ye Wu

Daemian Dussault

Allison Laura Choy

Kimberly Petrov

Helen Mcguire

Helen McGuire

Olga Quiroga

Mariko Yamabe

Helen Maureen Mcguire

Daemian David Dussault

Thomas Durand-Reville

The present disclosure provides a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

CDK2 inhibitors

This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.

Compounds and compositions useful for treating disorders related to NTRK

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula (I): 

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Inhibitors of the fibroblast growth factor receptor

This disclosure relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants, such as compounds of Formula I: 

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R, R, Rand Rare described herein.

&#x3b2;-lactamase inhibitor compounds

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.

Beta-lactamase inhibitor compounds

Growing community of inventors

Sudbury, MA, United States of America

Neil Bifulco